Back to Results
First PageMeta Content
Health / Rab escort protein / Blindness / Emerging technologies / Gene delivery / Medical genetics / Molecular biology / Adeno associated virus and gene therapy of the human retina / Biology / Medicine / Choroideremia


Media  Inquiries:     Jessica  Rowlands   202-­‐729-­‐4089        
Add to Reading List

Document Date: 2015-01-20 18:11:11


Open Document

File Size: 163,40 KB

Share Result on Facebook

City

PHILADELPHIA / SPK / /

Company

Pfizer Inc. / Spark / /

Country

United States / /

/

Event

FDA Phase / Business Partnership / /

Facility

Pipeline of Potential Treatments / The Children’s Hospital of Philadelphia / The Children's Hospital of Philadelphia / University of Pennsylvania PHILADELPHIA / University of Pennsylvania / /

IndustryTerm

treatment for the disease / technology commercialization organization / manufacturing / treatment of hemophilia / manufacturing process / /

MedicalCondition

disease / international choroideremia community / hemophilia B. Spark / genetic diseases / hematologic and neurodegenerative disorders / Choroideremia / choroideremia program / night blindness / blindness / /

MedicalTreatment

gene therapy / /

Organization

the University of Pennsylvania / /

Person

Bennett / /

/

Position

Professor of Ophthalmology / founder and chief executive officer / president of the Choroideremia Research Foundation / scientific advisor / gene therapy leader / /

Product

Phase 3 / SPK / RPE65 / /

ProvinceOrState

Pennsylvania / /

Technology

gene therapy / /

URL

www.sparktx.com / www.sparktx.com/pipeline / /

SocialTag